 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- ||| TERN-701 / Terns Pharma
New P1 trial: CARDINAL- A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (clinicaltrials.gov) - Dec 8, 2023
P1, N=80, Not yet recruiting, Sponsor: Terns, Inc.
- TERN-701 / Terns Pharma
The Novel BCR::ABL1 Allosteric Inhibitor HS?10382/TERN?701 is Potent Against Mutations Resistant to Active Site Tyrosine Kinase Inhibitors (TKIs) and Acts Synergistically With TKIs in BCR::ABL1+ Cancer Cell Lines () - Jun 21, 2023 - Abstract #SOHO2023SOHO_140;
TERN-701/HS-10382 retains activity against the T315I gatekeeper mutation, which confers resistance to all approved active site TKIs except for ponatinib, which has known safety liabilities. These data support the continued development of TERN-701/ HS-10382 for the treatment of CML.
- TERN-701 / Terns Pharma
A PHASE 1 MULTICENTER OPEN-LABEL DOSE-ESCALATION AND DOSE- EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, EFFICACY OF HS-10382 (TERN-70) IN CHRONIC MYELOID LEUKEMIA PATIENTS () - May 12, 2023 - Abstract #EHA2023EHA_2807;
P1
Clinical trial information: NCT05367700. Phase I, Chronic myeloid leukemia, BCR-ABL
- TERN-701 / Terns Pharma
A phase 1, multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of HS-10382 (TERN-701) in patients (pts) with chronic myeloid leukemia (CML). (Available On Demand; Poster Bd # 207a) - Apr 26, 2023 - Abstract #ASCO2023ASCO_856;
P1
This study is ongoing (enrollment underway for Part 1, dose 3 as of February 2023) with 7 participating study sites in China. Clinical trial information: NCT05367700.
- ||| TERN-701 / Terns Pharma
Enrollment open, Trial completion date, Trial primary completion date: A Study of HS-10382 in Patients With Chronic Myeloid Leukemia. (clinicaltrials.gov) - Jan 13, 2023
P1, N=108, Recruiting, Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.
Clinical trial information: NCT05367700. Not yet recruiting --> Recruiting | Trial completion date: Sep 2024 --> Sep 2026 | Trial primary completion date: Dec 2022 --> Dec 2024
- ||| TERN-701 / Terns Pharma
New P1 trial: A Study of HS-10382 in Patients With Chronic Myeloid Leukemia. (clinicaltrials.gov) - May 10, 2022
P1, N=108, Not yet recruiting, Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.